People with schizophrenia have roughly twice the prevalence of obesity compared with the general population, and roughly three times the prevalence of central (abdominal) obesity. The conversation about why this happens almost always starts with antipsychotic medication — and reasonably so. But antipsychotics are only one piece of a much larger picture, and treating obesity in this population means understanding all of them.
Obesity in schizophrenia results from a combination of antipsychotic side effects, illness-related metabolic vulnerability that pre-dates treatment, lifestyle and food-environment factors, and reduced access to weight-management care — and addressing only the medication usually addresses only part of the problem.
The shape of the problem
A 2015 systematic review by Vancampfort and colleagues in World Psychiatry pooled data from over 25,000 people with schizophrenia and found obesity prevalence around 50% (Vancampfort et al., 2015). Central obesity, the type most strongly tied to cardiometabolic risk, was even more elevated. The differences begin early — even first-episode patients show altered fat distribution and metabolic markers compared with controls.
Antipsychotic medication
The well-known piece. Different agents have very different weight profiles:
- High weight-gain risk: olanzapine, clozapine.
- Moderate risk: quetiapine, risperidone, paliperidone, iloperidone.
- Lower risk: aripiprazole, brexpiprazole, cariprazine, asenapine.
- Generally weight-neutral: ziprasidone, lurasidone, lumateperone, pimavanserin, xanomeline-trospium.
The mechanisms involve antagonism of serotonin 5-HT2C and histamine H1 receptors, alterations in leptin and ghrelin signalling, increased hunger, reduced satiety, and altered insulin and glucose handling. The Leucht network meta-analysis in The Lancet ranked agents by weight effect.
Illness-related vulnerability
Pillinger and colleagues examined antipsychotic-naive first-episode patients and found altered fasting glucose, insulin resistance, and dysregulated lipids before any medication was given (Pillinger et al., 2019, Molecular Psychiatry). This suggests a shared biological vulnerability between psychosis and metabolic disease — possibly involving inflammation, mitochondrial function, and HPA-axis dysregulation. Some genetic loci associated with schizophrenia overlap with loci associated with BMI and type 2 diabetes.
Implication: even on weight-neutral antipsychotics, people with schizophrenia carry baseline metabolic risk that the general population does not.
Negative symptoms and cognitive symptoms
The negative-symptom side of schizophrenia — reduced motivation, anhedonia, low energy, blunted goal-directed behaviour — directly affects exercise, food preparation, and grocery shopping. Cognitive symptoms make planning meals, reading nutrition labels, and tracking intake difficult. These are not simply "lifestyle choices" — they are symptoms of the illness expressed through the food environment.
Food environment and economics
People with serious mental illness are more likely to live in:
- Lower-income neighbourhoods with limited access to fresh produce
- Supportive housing or group homes where food is provided in bulk and limited variety
- Settings where calorie-dense, low-cost food is the only affordable option
- Areas with limited safe walking infrastructure or recreation facilities
These structural factors shape calorie intake and physical activity in ways that no medication switch will fix.
Sleep and circadian disruption
Disrupted sleep — common in schizophrenia and worsened by some antipsychotics — independently raises obesity risk through hormonal effects on hunger, glucose handling, and energy expenditure. See our sleep hygiene guide.
Smoking effects after cessation
Smoking suppresses appetite and raises metabolic rate. Quitting often produces weight gain (typically 4–10 kg over the first year), which is a real but very worthwhile trade-off for cardiovascular health. Anticipating and supporting this is part of cessation planning.
What helps
Antipsychotic choice
When clinically possible, choosing or switching to a more weight-neutral agent. The weight-gain management article outlines the evidence on switching from olanzapine to aripiprazole, lurasidone, or ziprasidone — the data are reasonably strong.
Metformin
Adding metformin to an existing antipsychotic regimen reduces or prevents weight gain in multiple randomised trials (our metformin overview).
GLP-1 receptor agonists
Semaglutide and liraglutide produce substantial weight loss in the general obesity population and are now being studied specifically in people on antipsychotics. Early data are encouraging.
Olanzapine/samidorphan (Lybalvi)
An FDA-approved combination of olanzapine with the opioid antagonist samidorphan, designed to mitigate olanzapine-associated weight gain (our overview).
Structured lifestyle programs
The ACHIEVE trial published in NEJM in 2013 demonstrated that an 18-month behavioural weight-loss intervention adapted for serious mental illness produced sustained, modest weight loss (Daumit et al., 2013). The STRIDE trial showed similar findings. Programs need to be intensive, frequent, and adapted for cognitive and motivational symptoms.
Bariatric surgery
Increasingly considered for people with severe obesity and serious mental illness when other options have failed. Outcomes appear comparable to those without mental illness when patients are stable and supported, though long-term studies are still emerging.
Rapid unintentional weight gain (more than 7% of body weight in three months on a stable antipsychotic), new symptoms of diabetes (extreme thirst, frequent urination), or sleep apnoea symptoms (loud snoring with witnessed apnoeas, daytime somnolence) — these warrant prompt medical review.
Beyond the scale
BMI is a coarse measure. Waist circumference, fasting lipids, fasting glucose or HbA1c, blood pressure, and physical fitness all matter independently of BMI. A person with schizophrenia who is overweight but exercising regularly, with normal blood pressure, lipids, and glucose, is in a different cardiometabolic situation than one with the same BMI who is sedentary and metabolically unwell.
The big picture
Obesity in schizophrenia is not solved by medication switches alone, by lifestyle changes alone, or by metformin alone. It is solved — to the extent it is solved — by addressing all of the contributing factors at once: choosing the right antipsychotic, screening for and treating metabolic disease, supporting structured lifestyle change, building food environments that work, and treating the negative and cognitive symptoms that affect daily function. Patients, families, and care teams who insist on this kind of integrated approach get better results than those who try to fix it one piece at a time.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.